MY155657A - 5-(2-{ [6- (2,2-difluoro-2-phenylethoxy) hexyl] amino}-1-hydroxyethyl)-8-hydroxyquinolin-2 (1h)-one for the treatment of lung function - Google Patents

5-(2-{ [6- (2,2-difluoro-2-phenylethoxy) hexyl] amino}-1-hydroxyethyl)-8-hydroxyquinolin-2 (1h)-one for the treatment of lung function

Info

Publication number
MY155657A
MY155657A MYPI2011003847A MYPI2011003847A MY155657A MY 155657 A MY155657 A MY 155657A MY PI2011003847 A MYPI2011003847 A MY PI2011003847A MY PI2011003847 A MYPI2011003847 A MY PI2011003847A MY 155657 A MY155657 A MY 155657A
Authority
MY
Malaysia
Prior art keywords
lung function
hydroxyquinolin
phenylethoxy
difluoro
hexyl
Prior art date
Application number
MYPI2011003847A
Other languages
English (en)
Inventor
Ruf Thorsten
Massana Montejo Eric
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MY155657A publication Critical patent/MY155657A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2011003847A 2009-02-18 2010-02-18 5-(2-{ [6- (2,2-difluoro-2-phenylethoxy) hexyl] amino}-1-hydroxyethyl)-8-hydroxyquinolin-2 (1h)-one for the treatment of lung function MY155657A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382020A EP2221055A1 (en) 2009-02-18 2009-02-18 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function

Publications (1)

Publication Number Publication Date
MY155657A true MY155657A (en) 2015-11-13

Family

ID=40833525

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011003847A MY155657A (en) 2009-02-18 2010-02-18 5-(2-{ [6- (2,2-difluoro-2-phenylethoxy) hexyl] amino}-1-hydroxyethyl)-8-hydroxyquinolin-2 (1h)-one for the treatment of lung function

Country Status (32)

Country Link
US (2) US20120029014A1 (OSRAM)
EP (2) EP2221055A1 (OSRAM)
JP (1) JP2012518019A (OSRAM)
KR (1) KR20110123742A (OSRAM)
CN (2) CN105326838A (OSRAM)
AR (1) AR075432A1 (OSRAM)
AU (1) AU2010214854A1 (OSRAM)
CA (1) CA2749059C (OSRAM)
CL (1) CL2011002001A1 (OSRAM)
CO (1) CO6361939A2 (OSRAM)
CY (1) CY1114484T1 (OSRAM)
DK (1) DK2398473T3 (OSRAM)
EA (1) EA022442B1 (OSRAM)
EC (1) ECSP11011336A (OSRAM)
ES (1) ES2430596T3 (OSRAM)
HR (1) HRP20130917T1 (OSRAM)
IL (1) IL213979A0 (OSRAM)
ME (1) ME01757B (OSRAM)
MX (1) MX2011008577A (OSRAM)
MY (1) MY155657A (OSRAM)
NZ (1) NZ593727A (OSRAM)
PE (1) PE20120419A1 (OSRAM)
PL (1) PL2398473T3 (OSRAM)
PT (1) PT2398473E (OSRAM)
RS (1) RS52951B (OSRAM)
SG (2) SG173091A1 (OSRAM)
SI (1) SI2398473T1 (OSRAM)
TW (2) TW201031408A (OSRAM)
UA (1) UA103370C2 (OSRAM)
UY (1) UY32414A (OSRAM)
WO (1) WO2010094483A1 (OSRAM)
ZA (1) ZA201104654B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
EP2668941A1 (en) * 2012-05-31 2013-12-04 Almirall, S.A. Novel dosage form and formulation of abediterol

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688U1 (it) 1979-02-05 1980-08-05 Chiesi Paolo Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
ES2113889T3 (es) 1990-09-26 1998-05-16 Pharmachemie Bv Dispositivos inhaladores provistos de un deposito para varias dosis de producto de inhalacion, dispositivo de transporte y camaras de turbulencia.
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
CA2152088C (en) 1992-12-18 1999-12-07 Thomas J. Ambrosio Inhaler for powdered medications
AU718263B2 (en) 1995-04-14 2000-04-13 Smithkline Beecham Corporation Metered dose inhaler for salmeterol
CN1325129C (zh) 1995-06-21 2007-07-11 Meda制药有限及两合公司 带整体计量装置的药筒和药粉吸入器
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2265276B1 (es) * 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
FR2903168B1 (fr) * 2006-06-30 2008-08-22 Fayard Eliane Bruleur pour realiser la combustion de substances reputees difficilement combustibles
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico

Also Published As

Publication number Publication date
ME01757B (me) 2014-09-20
CY1114484T1 (el) 2016-10-05
SG173091A1 (en) 2011-08-29
TW201442711A (zh) 2014-11-16
PL2398473T3 (pl) 2013-12-31
EA022442B1 (ru) 2016-01-29
EP2398473A1 (en) 2011-12-28
JP2012518019A (ja) 2012-08-09
ZA201104654B (en) 2012-02-29
AR075432A1 (es) 2011-03-30
AU2010214854A1 (en) 2011-07-21
CL2011002001A1 (es) 2011-11-11
PE20120419A1 (es) 2012-05-09
TW201031408A (en) 2010-09-01
CA2749059A1 (en) 2010-08-26
CO6361939A2 (es) 2012-01-20
US20120029014A1 (en) 2012-02-02
MX2011008577A (es) 2011-09-06
EP2221055A1 (en) 2010-08-25
ES2430596T3 (es) 2013-11-21
NZ593727A (en) 2013-07-26
CA2749059C (en) 2017-08-01
RS52951B (sr) 2014-02-28
IL213979A0 (en) 2011-08-31
SI2398473T1 (sl) 2013-11-29
PT2398473E (pt) 2013-09-30
HRP20130917T1 (hr) 2013-11-08
KR20110123742A (ko) 2011-11-15
DK2398473T3 (da) 2013-10-21
US20140343097A1 (en) 2014-11-20
EA201101210A1 (ru) 2012-03-30
EP2398473B1 (en) 2013-07-24
UA103370C2 (uk) 2013-10-10
WO2010094483A1 (en) 2010-08-26
ECSP11011336A (es) 2011-10-31
SG2014012827A (en) 2014-04-28
UY32414A (es) 2010-07-30
HK1159990A1 (en) 2012-08-10
CN105326838A (zh) 2016-02-17
CN102325530A (zh) 2012-01-18

Similar Documents

Publication Publication Date Title
MY155657A (en) 5-(2-{ [6- (2,2-difluoro-2-phenylethoxy) hexyl] amino}-1-hydroxyethyl)-8-hydroxyquinolin-2 (1h)-one for the treatment of lung function
MX2012002179A (es) Compuestos heterociclicos de oxima.
MX2012002875A (es) Derivados de 6-amino-quinazolina o 3-ciano-quinolina, metodos de preparacion y usos farmaceuticos de los mismos.
NZ590782A (en) 6-Amino-2-{ [(1S)-1-methylbutyl]oxy} -9-[5-(piperidin-1-yl)pentyl]-7,9-dihydro-8H-purin-8-one and pharmaceutical uses thereof
PH12012502569A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
WO2012047017A3 (ko) 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물
AR065247A1 (es) Sal de napadisilato y/o heminapadisilato de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino]-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona,composiciones farmaceuticas que las contienen y usos en el tratamiento del asma y otras enfermedades pulmonares.
MX2015002511A (es) Compuestos de dihidropirimidina y su aplicacion en productos farmaceuticos.
UA115320C2 (uk) Інгібітори кінази
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
MY183373A (en) Pyridine and pyrazine derivatives as protein kinase modulators
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
PH12014500417A1 (en) 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-l-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
SG176628A1 (en) Aminopyrrolidinone derivatives and uses thereof
MY149854A (en) Novel aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
CL2011002212A1 (es) Procedimiento para la preparacion de 5-(2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona utilizando xileno como solvente.
MX2012001529A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-piridazin-6-ilo como moduladores de cinasa de tirosina c-met.
NO20080501L (no) Kinolinderivater som antibakterielle midler
EA200800513A1 (ru) Производные хинолина в качестве антибактериальных средств
MY173812A (en) 2-pyridone compound
PH12014500774A1 (en) Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via a novel intermediate
TH123958A (th) 5-(2-{[6-(2,2-ไดฟลูออโร-2-ฟีนิลเอทธอกซี)เฮกซิล]อะมิโน}-1-ไฮดรอกซีเอทธิล)-8-ไฮดรอกซีควิโนลิน-2(1h)-โอน สำหรับการบำบัดการทำงานของปอด